FDA Brief

Warning letters Devices

FDA warning letter to

Turkuaz Sağlik Hizmetleri Medikal Temizlik Kimyasa

High riskIssued Dec 29, 2022Posted Jan 10, 2023Center for Devices and Radiological Health

FDA warns Turkish ultrasound gel maker Turkuaz over broad quality-system violations found in 2022 inspection.

What happened

FDA inspected the Turkuaz facility in Esenyurt-Istanbul, Turkey, from September 19 to September 23, 2022, and found the firm manufactures ultrasound gel products. FDA said the devices are adulterated (not in compliance with the law) because manufacturing methods, facilities, or controls do not conform to the device quality-system rule (CGMP). The firm responded on October 14 and November 30, 2022, but FDA found several responses inadequate and listed violations including design validation, complaint handling, supplier evaluation, design changes, cleanroom hygiene, and device history records.

What FDA found

  1. The firm did not keep raw data to support its design validation tests for sterile and non-sterile ultrasound gels, or document all validation results in the design history file.

    21 CFR 820.30(g)
  2. The complaint procedure did not ensure distributor complaints reached the firm or were reviewed for possible reports to FDA, and a 2021 complaint about black/dark blue fragments in sterile gel was not investigated.

    21 CFR 820.198(a)
  3. The firm had not documented an evaluation of its irradiation contract sterilizer and had no agreement to ensure notification of changes to sterilization processes.

    21 CFR 820.50(a)
  4. The firm changed preservatives and a neutralizing agent in its Konix gels but did not have raw validation data and did not evaluate patient risks from the changes in its risk analysis.

    21 CFR 820.30(i)
  5. During the inspection, a filling-line operator in a Class D cleanroom had hair outside her hair bonnet, and an empty water bottle was in a trash bin next to the cleanroom.

    21 CFR 820.70(d)
  6. Device history records for Konix sterile and non-sterile ultrasound gels did not contain the primary identification label and labeling used for production units.

    21 CFR 820.184

What FDA wants

FDA asks the firm to respond in writing within 15 business days with the specific steps taken to correct the violations and prevent recurrence, including documentation of corrective actions and a timetable if work will take longer, and to provide English translations of non-English documents.

Who should pay attention

  • U.S. distributors and brands selling imported ultrasound gels
  • contract sterilizers and suppliers to device makers
  • quality teams managing complaints and design changes

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk